Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Eccleston

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Gynecologic Oncology|February 2, 2019
Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian modelPaul Hoskins, Anthony Eccleston, Manjusha Hurry, et al.
International Journal of Technology Assessment in Health Care|May 20, 2020
Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer developsManjusha Hurry, Anthony Eccleston, Matthew Dyer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 15, 2017
A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian CancerAnthony Eccleston, Anthony Bentley, Matthew Dyer, et al.
Pharmacoeconomics - Open|August 18, 2024
Economic Impact of Bladder Cancer in the USAOtavio Clark, Tulio Sarmento, Anthony Eccleston, et al.
Dermatology and Therapy|December 8, 2021
Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic DermatitisHoward Thom, Vincent Cheng, Edna Keeney, et al.
Future Oncology (London, England)|August 2, 2023
Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in ScotlandSimone Critchlow, Ash Bullement, Simon Crabb, et al.
The Patient|March 11, 2026
Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder CancerBrad Mason, Anthony Eccleston, Lara Ayala-Nunes, et al.
JAMA Network Open|May 25, 2019
Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast CancerZoe Kemp, Alice Turnbull, Shawn Yost, et al.
JAMA Network Open|May 21, 2026
Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell CarcinomaNeil J Shah, Yaa Ababio, Anthony Eccleston, et al.
Nature Medicine|July 21, 2025
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trialNeal D Shore, Thomas B Powles, Jens Bedke, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Gynecologic Oncology|February 2, 2019
Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian modelPaul Hoskins, Anthony Eccleston, Manjusha Hurry, et al.
International Journal of Technology Assessment in Health Care|May 20, 2020
Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer developsManjusha Hurry, Anthony Eccleston, Matthew Dyer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 15, 2017
A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian CancerAnthony Eccleston, Anthony Bentley, Matthew Dyer, et al.
Pharmacoeconomics - Open|August 18, 2024
Economic Impact of Bladder Cancer in the USAOtavio Clark, Tulio Sarmento, Anthony Eccleston, et al.
Dermatology and Therapy|December 8, 2021
Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic DermatitisHoward Thom, Vincent Cheng, Edna Keeney, et al.
Future Oncology (London, England)|August 2, 2023
Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in ScotlandSimone Critchlow, Ash Bullement, Simon Crabb, et al.
The Patient|March 11, 2026
Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder CancerBrad Mason, Anthony Eccleston, Lara Ayala-Nunes, et al.
JAMA Network Open|May 25, 2019
Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast CancerZoe Kemp, Alice Turnbull, Shawn Yost, et al.
JAMA Network Open|May 21, 2026
Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell CarcinomaNeil J Shah, Yaa Ababio, Anthony Eccleston, et al.
Nature Medicine|July 21, 2025
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trialNeal D Shore, Thomas B Powles, Jens Bedke, et al.
Pageof 2